The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

Blood

Volumn 119, Issue 14, 2012, Pages 3276-3284

  Müller, Carsten ^a   Murawski, Niels ^b   Wiesen, Martin H J ^a   Held, Gerhard ^b   Poeschel, Viola ^b   Zeynalova, Samira ^c   Wenger, Michael ^d   Nickenig, Christina ^e   Peter, Norma ^f   Lengfelder, Eva ^g   Metzner, Bernd ^h   Rixecker, Tanja ^b   Zwick, Carsten ^b   Pfreundschuh, Michael ^b   Reiser, Marcel ⁱ  

^a Institut für Pharmakologie der Uniklinik   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f CARL THIEM KLINIKUM   (Germany)

^g UNIVERSITY OF MANNHEIM   (Germany)

^h Universitätsklinik für Onkologie und Hämatologie   (Germany)

ⁱ German Hodgkin Study Group   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GERIATRIC PATIENT; HUMAN; INFUSION; LARGE CELL LYMPHOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SEX DIFFERENCE; SIMULATION; STEADY STATE;

EID: 84859609431     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-380949     Document Type: Article

References (35)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
2. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-3127. (Pubitemid 46638950)
3. Pfreundschuh M, Truemper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the Mabthera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
4. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-116.
5. Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol. 2007;62(1):43-52. (Pubitemid 46330791)
6. Zwick C, Hartmann F, Zeynalova S, et al. Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol. 2011;22(8):1872-1877.
7. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188-2195. (Pubitemid 27392702)
8. Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol. 1998;9(5):527-534. (Pubitemid 28270641)
9. Iacona I, Lazzarino M, Avanzini MA, et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit. 2000;22(3):295-301. (Pubitemid 30346445)
10. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992;22(3):155-163.
11. Blasco H, Chatelut E, de Bretagne IB, Congy-Jolivet N, Le Guellec C. Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Fundam Clin Pharmacol. 2009;23(5):601-608.
12. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. 2010;70(11):1445-1476.
13. Li J, Levi M, Charoin JE, et al. Rituximab exhibits a long half-life based upon a population pharmacokinetic analysis in non-Hodgkin's lymphoma patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110(11):700.
14. Tran L, Baars JW, Aarden L, Beijnen JH, Huitema AD. Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Hum Antibodies. 2010;19(1):7-13.
15. Takao T, Kobayashi Y, Kuroda J, et al. Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis. Am J Hematol. 2004;77(4):419-420. (Pubitemid 39578336)
16. Tokar M, Rogachev B, Levi I, et al. Rituximab in a patient with acute renal failure due to B-cell lymphomatous infiltration of the kidneys. Leuk Lymphoma. 2004;45(4):819-820. (Pubitemid 38256049)
17. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005;45(7):792-801. (Pubitemid 40875331)
18. Josting A, Sieniawski M, Glossmann JP, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol. 2005;16(8):1359-1365. (Pubitemid 41158482)
19. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-4190.
20. Tobinai K, Igarashi T, Itoh K, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol. 2004;15(5):821-830. (Pubitemid 38714746)
21. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999;10(6):655-661. (Pubitemid 29342370)
22. Saven A, Grillo-Lopez AJ, Janakiraman N, et al. Rituximab: Pharmacokinetic/pharmacodynamic correlations of extended dosing in patients with relapsed low-grade or follicular non-Hodgkin lymphoma (LG/F) [abstract]. Blood (ASH Annual Meeting Abstracts). 2000;96(11):730.
23. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9(9):995-1001. (Pubitemid 28496709)
24. Mangel J, Buckstein R, Imrie K, et al. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol. 2003;14(5):758-765. (Pubitemid 36621777)
25. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758. (Pubitemid 34525533)
26. Ahlgrimm M, Pfreundschuh M, Kreuz M, et al. The impact of Fc-gamma receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood. 2011;118(17):4657-4662.
27. Jilma-Stohlawetz P, Reiter RA, Panzer S, et al. Pharmacokinetics (PK) of S/D treated anti-D immunoglobulin after intramuscular injection in healthy volunteers: gender differences in PK. Transfus Apher Sci. 2005;33(2):135-140. (Pubitemid 41329880)
28. Vachharajani NN, Raymond RH, Shyu WC, Stouffer BC, Boulton DW. The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase. Br J Clin Pharmacol. 2011;72(5):775-786.
29. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499-523. (Pubitemid 38263851)
30. Gisselbrecht C, Glass B, Mounier N, et al. Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 positive diffuse large B-cell lymphoma: CORAL final analysis [abstract]. J Clin Oncol. 2011;29(155):505s.
31. Pfreundschuh M, Held G, Zeynalova S, et al. Improved outcome of elderly poor-prognosis DLBCL patients with 6xCHOP-14 and 8 applcations of rituximab given over an extended period: Results of the SMARTE-R-CHOP-14 trial of the German High-Grad Non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):272-273.
32. Cunningham D, Smith P, Mouncey P, et al. R-CHOP-14 vs. R-CHOP-21: result from a phase III trial for the treatment of newly diagnosed diffuse large B-cell non-Hodgkin lymphoma [abstract]. J Clin Oncol. 2011;29(155):504s.
33. Delarue R, Tilly H, Salles G, et al. R-CHOP-14 compared to R-CHOP-21 in elderly patients with diffuse large B-cell lymphoma: results of the second interim analysis of the LNH03-6B GELA study [abstract]. Ann Oncol. 2011;22(suppl 4):iv117.
34. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634-641. (Pubitemid 38970554)
35. Regazzi MB, Iacona I, Avanzini MA, et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit. 2005;27(6):785-792. (Pubitemid 44391736)